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Introduction 
Materials and Methods 
Discussion 
• Preeclampsia is a syndrome defined by the new 
onset of hypertension (SBP >140 mmHg or DBP >90 
mmHg) and proteinuria (24 hour urine protein >300 
mg) after 20 weeks of gestation. 
• Affects 3-5% of all pregnancies can result in serious 
maternal and neonatal morbidity and mortality. 
• Delivery of the neonate is the only definitive 
treatment, thus preeclampsia is a major cause of 
preterm birth. 
•Although gestational hypertension is common, only 
a minority eventually develop severe preeclampsia 
with serious complications.  
•A blood test which could predict maternal or 
neonatal complications in women with suspected 
preeclampsia would be useful for clinical risk 
stratification.  













• A single-center prospective cohort study of 315 pregnant 
women who presented to GWUH Labor and Delivery service with a 
clinical suspicion of preeclampsia between February 2007 and 
November 2011. Informed consent was obtained. 
 
Baseline demographic information and medical history was collected 
on each patient including maternal age, ethnicity, body mass index, 
tobacco and other substance use, gestational age, medical problems 
and obstetric history.  
 
Serum samples were obtained from each enrolled subject within 24 
hours of admission, and sFlt1, PlGF and sEng ELISA assays were 
performed in duplicate by a blinded laboratory technician at the 
University of Massachusetts. 
 
Primary outcome variable: Preeclampsia defined as the new onset 
of hypertension and proteinuria after 20 weeks gestation, according to 
guidelines published by NHLBI and ACOG. Hypertension was defined 
as SBP≥140 or DBP≥90 on at least 2 occasions at least 4 hours 
apart. Proteinuria was defined as >300mg of protein in a 24hr urine 
specimen, spot urine protein:creatinine ratio >0.3, or urine dipstick of 
1+ or higher. Additionally: 
 Women with chronic hypertension and without proteinuria prior 
to 20 wks gestation: diagnosis of preeclampsia required new 
onset proteinuria after 20 wks gestation 
 Women with baseline proteinuria, but without chronic 
hypertension: diagnosis of preeclampsia required new onset 
hypertension and worsening proteinuria 
 Women with chronic hypertension and baseline proteinuria prior 
to 20 wks: preeclampsia required worsening hypertension and 
one of the following: (1) elevated AST or ALT; (2) worsening 
proteinuria; (3) thrombocytopenia; or (4) eclampsia 
 
Secondary outcome was a composite of adverse maternal and 
neonatal complications, including any one of the following.  Maternal 
complciations: elevated liver enzymes, thrombocytopenia, oliguria, 
seizures, pulmonary edema or cerebral hemorrhage.  Neonatal 
complications: early preterm birth (<34 weeks), placental abruption, 
small for gestational age, NICU admission, fetal or neonatal demise.  
 
Statistical analysis: Wilcoxon rank sum tests were used to compare 
serum levels of biomarkers among women with and without pre-
eclampsia. A Kruskal-Wallis test with post-hoc comparisons was used 
to do a three-way comparison of the serum levels of the angiogenic 
factors between women without preeclampsia, women with 
preeclampsia and no complications and women with preeclampsia 
and complications. A logistic regression analysis, adjusted for race, 
obesity, renal disease, chronic hypertension, gestational age at time 
of sample collection was used to identify correlating variables. 
 Among a cohort of women presenting acutely with signs 
and symptoms suggestive of preeclampsia, women who 
eventually met diagnostic criteria for preeclampsia had 
lower serum PlGF levels at presentation as compared to 
women who did not meet preeclampsia criteria. 
sFlt1, sEng, and the sFlt1/PlGF ratio were not 
significantly different in women who did vs. those who did 
not meet criteria for preeclampsia  
 Women who developed preeclampsia with maternal or 
neonatal complications had lower serum PlGF levels at 
presentation as compared to women who developed 
preeclampsia without complications and women who did 
not meet criteria for preeclampsia. 
Serum PlGF may be a useful tool for risk stratification in 
women who present with signs/symptoms suggestive of 
preeclampsia.  
This tool, rooted in the fundamental pathogenesis of 
preeclampsia, could arm clinicians with a significant 
advance in the identification of high-risk patients, ensuring 
that women with a high likelihood of developing severe 
preeclampsia complications receive aggressive monitoring 
and intervention, while allowing women at low risk of 
complications to be managed conservatively. 
This is the first study to evaluate the utility of biomarkers 
for risk stratification in the triage setting. Larger studies are 
needed to confirm our result, and to establish the utility of 
PlGF for risk stratification in the clinical setting. 
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Results 
Serum samples were processed as per methods and analyzed by ELISA. Statistical analysis showed that PlGF 
levels are significantly lower in the pre-eclamptic women. Serum levels of Sflt1 and sEng are not 
significantly different between the two groups. The ratio of Sflt1 to PlGF did not reach significance when 
compared between groups, though a trend towards an increase was noted (p=0.08). 
 
Table 2. Serum levels of PlGF are significantly lower in women with preeclampsia compared 
to women without pre-eclampsia.  
Serum levels of PlGF  are significantly lower in women with preeclampsia compared to women without. Most 
importantly, PlGF is further decreased in women with both preeclampsia and documented maternal and neonatal 
complications. Serum levels of Sflt1 and Eng were not significantly different among the two groups and there was no 
difference in serum levels among the women who developed complications. The ratio of Sflt to PlGF failed to show a 
statistically significant difference between any groups.  
Table 3 Serum levels of PlGF are significantly lower in women with pre-eclampsia and 
even lower in women with pre-eclampsia and complications compared with women with 








Mean maternal age in 
years (SE) 
29.5 (0.7) 30.8 (0.4) 
Race % (N) % (N) 
White 18 (15) 27 (59) 
Black 71 (60) 69 (133) 
Other 12 (10) 12 (26) 
Smoking 
Never 82 (70) 92 (201) 
Former 13 (11) 5 (11) 
Current 5 (4) 3 (6) 
Chronic HTN 35 (30) 20 (43) 
Diabetes 6 (5) 6 (13) 
Renal disease 2 (2) 2 (4) 
Gravidity  
(excluding  current 
pregnancy) 
0 33 (28) 32 (69) 
1-3 44 (37) 51 (111) 
4+ 24 (20) 17 (37) 
Prior history of 
preeclampsia 
15 (13) 10 (21) 
Delivery method 
C-section 58 (49) 49 (111) 
Vaginal induced 24 (20) 25 (54) 
Vaginal spontaneous 19 (16) 26 (57) 
Gestational age at 
delivery (weeks) 
37+ 62 (53) 76 (163) 
<37 38 (32) 24 (51) 
Table 1. Characteristics of women who 
were enrolled in the study and later 
identified to have or not have 
preeclampsia. 
 
Variable No Pre-eclampsia 
(n=215) 
Pre-eclampsia (n=83) Wilcoxon p-value 
PIGF 155 (3-3575) 117 (8.5-797) 0.0295 
sFlt1/PlGF 69.4 (2.2-1619) 95.7 (2-1982) 0.0843 
sFlt1 9609 (140-119,564) 10689 (939-76,154) 0.56 
Eng 15.5 (2.5, 297) 20.3 (3.2-161) 0.17 









PIGF 155 (3-3575) 129 (24-798) 78 (8.5-653) 0.0285 
sFlt/PlGF 69.4 (2.2-1619) 79.5 (3.3-470) 145 (2-1985) 0.11 







sEng 15.5 (2.5, 297) 18.6 (3.6-65) 32.4 (3.2-161) 0.28 
Variable Adjusted OR 95% CI 
PIGF per 100 unit 
change 
0.83 0.69, 0.99 
Race 
    Black vs. White 1.04 0.48, 2.26 
    Other vs. White 1.22 0.44, 3.37 
Gestational age 
at sample (wks) 
0.91 0.85, 0.98 
Gravidity 1.07 0.93, 1.25 
Preeclampsia 
history 
1.12 0.46, 2.69 
History of renal 
disease 
0.35 0.05, 2.56 
Chronic 
hypertension 
1.62 0.84, 3.11 
Smoking status 
     Former vs. 
Never 
1.85 0.46, 7.37 
     Current vs. 
Never 
4.43 1.64, 11.95 
Maternal age 
(yrs) 
0.95 0.90, 0.99 
Table 4. Serum levels of PlGF, gestational 
age, current smoking status and maternal 
age are correlated with an increased 
incidence of preeclampsia. 
Table 4 Legend. Logistic regression analysis 
was performed and adjusted for race, renal 
disease, hypertension status, gravity and 
prior history of pre-eclampsia. Significant 
correlations are indicated in bold.  
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